CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 188 target
Drug / intervention
camrelizumab +1 moredrug
Likely dose
camrelizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04944914
NCT04944914Phase 3RecruitingOn TrackUpdated 2mo ago
Long Recruiting
CompareCT.gov

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma: A Multicenter Randomized Clinical Phase 3 Trial

Sun Yat-sen University·interventional·Posted Jun 30, 2021·Updated Apr 30, 2026

In Brief

A Phase 3 clinical trial evaluating camrelizumab and stereotactic body radiotherapy for Nasopharyngeal Carcinoma. Currently recruiting, targeting 188 participants across 1 site.

Detailed Summary

We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
CollaboratorsAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Guangdong Provincial People's Hospital

Timeline

Phase 3Recruiting
2022202320242025202620272028
First PostedJun 30, 2021
Enrollment StartJun 1, 2021
Primary CompletionJun 1, 2027
Study CompletionJun 1, 2028
TodayJul 1, 2026
Enrollment to primary: 6 yearsPosted 5.0 years agoPrimary completion in 11 months

Interventions

camrelizumabdrug

Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy

stereotactic body radiotherapyradiation

Patients receive stereotactic body radiotherapy for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.